Is GAN or MRK a better dividend investment in 2026?

GAN currently yields 101.52% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: GAN offers higher current income.

What is the dividend yield difference between GAN and MRK?

GAN has a forward dividend yield of 101.52% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 98.76 percentage points.

Home › Compare › GAN vs MRK

GAN vs MRK: Dividend Comparison 2026

GAN yields 101.52% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GAN wins by $4.09M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GAN

● Live price

101.52%

Share price

$1.97

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.15M

Annual income

$1,411,051.39

Full GAN calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — GAN vs MRK

📍 GAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GAN	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GAN + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GAN pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GAN

Annual income on $10K today (after 15% tax)

$8,629.44/yr

After 10yr DRIP, annual income (after tax)

$1,199,393.68/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, GAN beats the other by $1,191,065.27/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GAN + MRK for your $10,000?

GAN: 50%MRK: 50%

100% MRK50/50100% GAN

Portfolio after 10yr

$2.10M

Annual income

$710,424.77/yr

Blended yield

33.81%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GAN

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-3.6

Piotroski

3/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GAN buys

MRK buys

No recent congressional trades found for GAN or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGANMRK

Forward yield	101.52% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.15M	$56.8K ✓
Annual income after 10y	$1,411,051.39 ✓	$9,798.13
Total dividends collected	$3.71M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Hold	Buy

Year-by-year: GAN vs MRK ($10,000, DRIP)

Year	GAN Portfolio	GAN Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$20,852	$10,152.28	$11,206	$366.19	+$9.6K → GAN
2	$42,097	$19,784.89	$12,650	$502.35	+$29.4K → GAN
3	$82,373	$37,328.94	$14,407	$694.19	+$68.0K → GAN
4	$156,403	$68,264.51	$16,585	$967.82	+$139.8K → GAN
5	$288,488	$121,136.25	$19,342	$1,363.89	+$269.1K → GAN
6	$517,502	$208,819.97	$22,913	$1,947.19	+$494.6K → GAN
7	$903,811	$350,084.51	$27,662	$2,823.89	+$876.1K → GAN
8	$1,538,498	$571,419.57	$34,159	$4,173.35	+$1.50M → GAN
9	$2,555,248	$909,055.50	$43,337	$6,308.80	+$2.51M → GAN
10	$4,145,167	$1,411,051.39	$56,776	$9,798.13	+$4.09M → GAN

GAN vs MRK: Complete Analysis 2026

GAN — Stock

GAN Limited operates as a business-to-business (B2B) supplier of enterprise software-as-a-service solutions to online casino gaming and sports betting applications in the United States, Europe, Latin America, and internationally. The company operates in two segments, B2B and Business-to-Consumer (B2C). It offers and licenses GameSTACK, an internet gaming platform that provides turnkey technology solution for regulated real-money internet gambling, online sports betting, and virtual simulated gaming. The company also offers online sports betting, online casino game, and peer-to-peer poker services through its coolbet.com website, as well as a range of development, marketing, and customer support services designed to deploy and provide ongoing operational support for its software systems. It serves regional operators and individual tribal casino operators. The company was incorporated in 1999 and is headquartered in Irvine, California.

Full GAN Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this GAN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GAN vs SCHD GAN vs JEPI GAN vs O GAN vs KO GAN vs MAIN GAN vs JNJ GAN vs ABBV GAN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.